BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22357250)

  • 1. Preoperative PET/CT in early-stage breast cancer.
    Bernsdorf M; Berthelsen AK; Wielenga VT; Kroman N; Teilum D; Binderup T; Tange UB; Andersson M; Kjær A; Loft A; Graff J
    Ann Oncol; 2012 Sep; 23(9):2277-2282. PubMed ID: 22357250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
    Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
    Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
    J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.
    Heudel P; Cimarelli S; Montella A; Bouteille C; Mognetti T
    Int J Clin Oncol; 2010 Dec; 15(6):588-93. PubMed ID: 20809217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
    Cermik TF; Mavi A; Basu S; Alavi A
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan.
    Garami Z; Hascsi Z; Varga J; Dinya T; Tanyi M; Garai I; Damjanovich L; Galuska L
    Eur J Surg Oncol; 2012 Jan; 38(1):31-7. PubMed ID: 21937190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
    Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
    Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?
    Krammer J; Schnitzer A; Kaiser CG; Buesing KA; Sperk E; Brade J; Wasgindt S; Suetterlin M; Schoenberg SO; Sutton EJ; Wasser K
    Eur Radiol; 2015 Aug; 25(8):2460-9. PubMed ID: 25680729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
    Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting the accuracy of
    Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
    Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.